Key points from article :
Diaceutics CEO Peter Keeling is working to bridge the gap between pharmaceutical companies, diagnostics, and laboratories.
Hundreds of thousands of patients could be missing out on life-saving drugs.
Most medicines have been little tested and used to treat everyone broadly the same.
15 years ago a breast cancer patient would have been treated with the same type of cocktail of drugs, regardless.
But breast cancer is a whole series of different types of diseases.
Better identification of disease enables greater impact with the treatment.
